Swayv AI

Company Overview

Snapshot

Founded in December 2025, Swayv AI operates with 1–10 employees. The company has raised $1.5 million across one funding round from one investor. In February 2026, Swayv AI secured seed funding, with Mediterranean Towers Ventures participating.

Business overview

Swayv AI develops software for cardiologists and health systems, leveraging machine-learning models to analyze routine and exercise ECG data. Its core technology is designed to detect ischemic clues and cardiac-function changes that may be missed by standard interpretation, including in asymptomatic patients. The company aims to identify cardiac disease years before a major event, reduce misdiagnoses, and minimize unnecessary follow-up testing, serving the Digital Medical Diagnostics sector within Health Tech & Life Sciences.

Strategic signal

In February 2026, Swayv AI successfully raised $1.5 million in seed funding. This capital infusion, with participation from Mediterranean Towers Ventures, signals strong early investor confidence in the company's AI-driven approach to cardiac diagnostics. The funding will likely accelerate the development and potential regulatory clearance of its machine-learning system, positioning Swayv AI to advance its mission of early disease detection and improved patient outcomes in the health tech market.

Company Intelligence Q&A

What is Swayv AI's primary focus?

Swayv AI focuses on developing AI software to detect hidden cardiac disease from routine and stress ECGs, aiming to improve diagnostic accuracy and enable earlier intervention.

When was Swayv AI founded?

Swayv AI was founded in December 2025.

What is Swayv AI's product stage?

Swayv AI's product is currently in Beta stage.

Which investor participated in Swayv AI's seed funding round?

In February 2026, Mediterranean Towers Ventures participated in Swayv AI's seed funding round.

What problem does Swayv AI aim to solve?

Swayv AI aims to address the challenge of missed or delayed diagnoses of cardiac conditions by identifying subtle ischemic clues and cardiac-function changes that standard ECG interpretation might overlook, thereby reducing misdiagnoses and avoiding unnecessary follow-up testing.